Cutaneous Adverse Reactions Associated With Enfortumab Vedotin: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
April 2026
in “
Frontiers in Medicine
”
Studysummary This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on public-pages-files-2025.frontiersin.org →